Olanzapine tablets are taken by mouth, with or without food, for schizophrenia and bipolar disorder. They help reduce psychotic symptoms and stabilise mood by influencing dopamine and serotonin…
Olanzapine tablets are taken by mouth, with or without food, for schizophrenia and bipolar disorder. They help reduce psychotic symptoms and stabilise mood by influencing dopamine and serotonin signalling in the brain.
Olanzapine is an atypical antipsychotic used mainly for schizophrenia and bipolar disorder. It may reduce hallucinations, delusions, disorganised thinking, agitation, and manic symptoms. For some patients, it is continued as maintenance treatment after acute symptoms improve.
Olanzapine tablets contain olanzapine as the active medicine. The product is supplied for oral use, and the exact tablet strength should be confirmed with a healthcare professional before starting treatment.
Olanzapine is also used in combination with other psychiatric treatment plans when a specialist considers this appropriate. The dose may be adjusted gradually because the same strength can affect people differently.
Olanzapine is prescribed in clinical settings for:
The medicine does not remove the underlying diagnosis. Its purpose is to reduce symptoms and support sustained functioning while the treatment plan continues.
Olanzapine is supplied as oral pills or tablets. The prescribed regimen for the chosen strength must be confirmed with a healthcare professional before starting. Treatment is individualised according to the condition being treated, age, response, adverse effects, liver function, and other medicines.
The dose may be increased or reduced according to response and tolerability. A clinician may also select a different administration time when daytime sedation interferes with work or daily activities.
A common practical error is taking an additional tablet because sleep or agitation has not improved immediately. Olanzapine is not intended for unsupervised rapid dose changes.
The medicine works best when taken consistently rather than stopped as soon as distressing symptoms settle.
Olanzapine is not suitable for everyone. A known serious allergic reaction to olanzapine is a direct contraindication. The medicine also requires careful assessment in people with conditions that may worsen with sedation, postural hypotension, anticholinergic effects, seizures, or metabolic change.
The FDA prescribing information describes warnings concerning metabolic changes, orthostatic hypotension, tardive dyskinesia, seizures, and dementia-related psychosis mortality [3].
Olanzapine should not be used when:
Caution is also needed with glaucoma risk, urinary retention, prostate enlargement, seizure disorders, liver disease, low blood pressure, and previous diabetes. Pregnancy and breastfeeding require an individual treatment discussion because both untreated psychiatric illness and medicine exposure can affect clinical decisions.
Olanzapine can cause adverse effects even when it is clinically helpful. The most relevant long-term concern is metabolic change. Weight gain, increased appetite, higher blood glucose, and altered lipid levels may develop during treatment.
Common effects include:
The frequency and severity vary between individuals. Clinical guidelines recommend recording weight and assessing metabolic risk at baseline, then repeating checks during follow-up. Blood glucose or HbA1c and lipid testing may be needed, especially when weight rises or diabetes risk is present.
Metabolic effects can appear gradually, which makes them easy to overlook. A person may feel psychiatrically better while developing increased appetite or reduced activity. Regular meals, planned snacks, movement suited to physical ability, and timely blood tests can help identify changes early.
Patients often notice that evening hunger becomes stronger. Keeping high-calorie snack foods out of the immediate bedtime routine can be more practical than relying on willpower after sedation begins.
The National Institute for Health and Care Excellence recommends physical-health monitoring for people receiving antipsychotic treatment, including assessment of weight, glucose regulation, and lipids [2]. A sudden increase in thirst, frequent urination, unusual weakness, or unexplained weight change needs prompt medical attention because it may indicate significant glucose disturbance.
Urgent medical assessment is required for facial or throat swelling, breathing difficulty, widespread blistering rash, skin peeling, severe fever with muscle rigidity, collapse, or rapidly worsening confusion. These symptoms may indicate a serious allergic, neurological, or systemic reaction.
Rare but serious complications include seizures, severe movement disorders, neuroleptic malignant syndrome, and significant blood-pressure changes. Constipation that becomes severe, painful, or associated with vomiting also needs prompt assessment.
Olanzapine blocks several neurotransmitter receptors in the central nervous system. Its antipsychotic action is linked mainly to antagonism of dopamine D2 and serotonin 5-HT2A receptors. In plain terms, it reduces excessive signalling in pathways associated with psychosis while also influencing mood and emotional regulation.
The medication also has affinity for muscarinic cholinergic, histamine H1, and alpha-1 adrenergic receptors. These additional actions contribute to some useful and unwanted effects. H1 blockade can cause drowsiness and increased appetite. Muscarinic blockade may contribute to dry mouth or constipation. Alpha-1 blockade can cause dizziness when standing. These effects can affect daily functioning and should be discussed during follow-up.
| Receptor system | Clinical meaning | Possible patient effect |
|---|---|---|
| Dopamine D2 | Reduces excessive dopamine signalling | Fewer hallucinations, delusions, and thought disturbances |
| Serotonin 5-HT2A | Modulates dopamine release and mood pathways | Antipsychotic and mood-related effects |
| Histamine H1, muscarinic, alpha-1 | Produces secondary central and peripheral effects | Sleepiness, appetite increase, dry mouth, constipation, or postural dizziness |
Olanzapine differs from a selective serotonin reuptake inhibitor because it does not primarily increase serotonin by blocking its reuptake. It also differs from conventional antipsychotics through its wider receptor profile. This broader action can benefit psychosis and mania, yet it creates a greater need to monitor weight, glucose, lipids, and sedation.
The World Health Organization recognises antipsychotic treatment as part of care for schizophrenia and related psychotic disorders, alongside psychosocial support and follow-up [1].
Several avoidable mistakes can reduce benefit or increase harm:
One practical distinction matters: feeling calmer is not the same as full remission of psychosis or mania. Treatment decisions should consider sleep, thought organisation, functioning, mood, adverse effects, and relapse risk together.
Olanzapine differs from a selective serotonin reuptake inhibitor because it does not primarily increase serotonin by blocking its reuptake. It also differs from conventional antipsychotics through its wider receptor profile.
In clinical practice, psychiatrists usually assess olanzapine through two parallel questions: are psychotic or manic symptoms improving, and is the physical-health burden acceptable? A reduction in hallucinations may be a meaningful early gain, while weight, glucose, lipids, movement symptoms, and daytime alertness determine whether treatment remains suitable.
Doctors commonly advise keeping the regimen stable long enough to assess response unless a serious adverse effect appears. Abrupt discontinuation can be followed by insomnia, agitation, nausea, sweating, or return of psychiatric symptoms. A planned reduction is safer than stopping suddenly.
The choice of olanzapine can be reasonable when strong antipsychotic or antimanic activity is needed, yet its metabolic profile makes monitoring essential. Clinicians often discuss appetite, activity, sleep, alcohol, smoking, family history of diabetes, and previous treatment responses before settling on a long-term plan.
A useful appointment detail is to bring a list of actual medicines and supplements, including occasional diazepam, antihistamines, or anti-sickness tablets. These products may not appear important to the patient but can increase sedation or affect movement symptoms.
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors, while antidepressant medicines usually act through serotonin or noradrenaline reuptake pathways. Its receptor profile can address psychosis and mania, but it also increases the possibility of sedation and metabolic effects. NICE guidance published in 2014 places antipsychotic choice within an individual assessment of symptoms, physical health, and previous response. The active substance, not a trade name, determines the pharmacological identity.
Do not increase the tablets independently when improvement is slower than expected. The prescriber may review adherence, diagnosis, smoking status, interacting medicines, substance use, sleep, and the duration of treatment before changing the plan. FDA prescribing information reviewed in 2024 describes dose individualisation and monitoring for response and adverse reactions. Urgent help is needed if there is immediate danger, severe confusion, suicidal thinking, or rapidly escalating mania.
Take the missed dose when remembered unless the next dose is close; never double the dose to compensate. If more than one dose has been missed, the restart plan may depend on the treatment duration and the person’s clinical state. The EMA product information for olanzapine (2023) describes regular daily administration and cautions against unsafe dose changes. Keep the next appointment informed about repeated missed doses because this may resemble treatment failure.
Yes, weight gain and increased appetite are recognised adverse effects of olanzapine. The risk varies with treatment duration, personal metabolism, diet, activity, and previous exposure to antipsychotics. WHO guidance published in 2023 supports attention to physical health in people receiving antipsychotic treatment. Weight, waist measurement, glucose regulation, and lipids should be reviewed according to the clinical plan, especially after a noticeable appetite or weight change.
Olanzapine tablets may generally be taken with or without food, so meals do not usually determine the administration time. Taking the tablet at a consistent time can make missed doses less likely. The EMA product information for olanzapine (2023) describes oral administration without requiring a meal for absorption. Alcohol remains a separate concern because it can intensify sedation, impaired coordination, and dizziness.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
I took olanzapine for several weeks after a severe manic episode. My sleep settled first, then my thoughts became less pressured. The difficult part was increased appetite in the evening, so my prescriber arranged weight and glucose monitoring.
Several weeks 10 Nov 2026The tablets reduced frightening voices over the first month. I felt steadier, but morning drowsiness made driving impossible for me at first. Changing the timing helped, although constipation became an issue that needed treatment.
The first month 5 Nov 2026I noticed improvement in agitation after starting treatment, but I expected the rest of the symptoms to disappear immediately. That did not happen. Regular appointments helped the psychiatrist judge the response instead of me changing the dose myself.
13 Oct 2026Olanzapine helped my sleep and suspicious thoughts, but I stopped taking it after weight gain. Symptoms returned later, and restarting treatment required medical supervision. I wish I had reported the weight change earlier rather than stopping abruptly.
26 Oct 2026
